Targeting a Signaling Pathway Activated by Acidic Tumor Environment Restores Treatment Response to PARP Inhibitors in Ovarian Cancer

Researchers at The University of Texas MD Anderson Cancer Center have discovered a promising strategy to overcome PARP inhibitor resistance in ovarian cancer, one of the most common barriers to the long-term effectiveness of this widely used treatment.